{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:50:33Z","timestamp":1794379833135,"version":"4.9.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1053\/j.seminoncol.2022.01.002","type":"journal-article","created":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T23:41:48Z","timestamp":1642894908000},"page":"94-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Examining health related quality of life outcomes in multiple myeloma: Past and future perspectives"],"prefix":"10.1053","volume":"49","author":[{"given":"Gil","family":"Hevroni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Korde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2022.01.002_bib0001","unstructured":"Institute NC. Cancer Stat Facts: Myeloma 2021."},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.002_bib0002","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.ejca.2006.01.065","article-title":"Epidemiology and outcomes research for MGUS, myeloma and amyloidosis","volume":"42","author":"Sirohi","year":"2006","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.002_bib0003","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29119","article-title":"Health-related quality of life in older adult survivors of selected cancers: data from the SEER-MHOS linkage","volume":"121","author":"Kent","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.002_bib0004","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/0277-9536(95)00116-O","article-title":"Clinical and public health perspectives and applications of health-related quality of life measurement","volume":"41","author":"Ebrahim","year":"1995","journal-title":"Soc Sci Med"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.002_bib0005","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/0277-9536(95)00112-K","article-title":"The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization","volume":"41","year":"1995","journal-title":"Soc Sci Med"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.002_bib0006","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1200\/JCO.1994.12.3.608","article-title":"Lessons learned from measuring health-related quality of life in oncology","volume":"12","author":"Osoba","year":"1994","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.002_bib0007","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.002_bib0008","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1600-0609.2009.01404.x","article-title":"What changes in health-related quality of life matter to multiple myeloma patients? A prospective study","volume":"84","author":"Kvam","year":"2010","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.002_bib0009","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-019-0181-0","article-title":"Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed\/refractory multiple myeloma","volume":"9","author":"Ludwig","year":"2019","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1053\/j.seminoncol.2022.01.002_bib0010","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41375-019-0480-2","article-title":"Convenience, satisfaction, health-related quality of life of once-weekly 70 mg\/m","volume":"33","author":"Moreau","year":"2019","journal-title":"Leukemia"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.002_bib0011","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jpainsymman.2011.06.019","article-title":"Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction","volume":"43","author":"Wagner","year":"2012","journal-title":"J Pain Symptom Manage"},{"issue":"12","key":"10.1053\/j.seminoncol.2022.01.002_bib0012","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00277-018-3446-y","article-title":"Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect\u00ae MM Registry","volume":"97","author":"Abonour","year":"2018","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.002_bib0013","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"8","key":"10.1053\/j.seminoncol.2022.01.002_bib0014","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1080\/10428194.2020.1747066","article-title":"Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"61","author":"Weisel","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.002_bib0015","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/10428194.2018.1523399","article-title":"Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales","volume":"60","author":"Tay","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"10.1053\/j.seminoncol.2022.01.002_bib0016","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1002\/cam4.3391","article-title":"Health-related quality of life of patients with multiple myeloma: a real-world study in China","volume":"9","author":"Li","year":"2020","journal-title":"Cancer Med"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.002_bib0017","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1634\/theoncologist.2017-0592","article-title":"Representation of minorities and elderly patients in multiple myeloma clinical trials","volume":"23","author":"Duma","year":"2018","journal-title":"Oncologist"},{"key":"10.1053\/j.seminoncol.2022.01.002_bib0018","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.critrevonc.2019.02.011","article-title":"Special considerations for the treatment of multiple myeloma according to advanced age, comorbidities, frailty and organ dysfunction","volume":"137","author":"Fraz","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.002_bib0019","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jgo.2020.10.009","article-title":"Disparities in treatment patterns and outcomes among younger and older adults with newly diagnosed multiple myeloma: a population-based study","volume":"12","author":"Mian","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.002_bib0020","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1016\/j.clml.2020.09.010","article-title":"Burden of treatment among older adults with newly diagnosed multiple myeloma","volume":"21","author":"Mian","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.002_bib0021","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2018.01.005","article-title":"Undertreatment of older patients with newly diagnosed multiple myeloma in the era of novel therapies","volume":"18","author":"Fakhri","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"10.1053\/j.seminoncol.2022.01.002_bib0022","first-page":"687","article-title":"A simple score, based on geriatric assessment, improves prediction of survival, and risk of serious adverse events in elderly newly diagnosed multiple myeloma patients","volume":"122","author":"M","year":"2013","journal-title":"Am Soc Hematol"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.002_bib0023","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2010.08.009","article-title":"The frailty syndrome: definition and natural history","volume":"27","author":"Xue","year":"2011","journal-title":"Clin Geriatr Med"},{"issue":"9","key":"10.1053\/j.seminoncol.2022.01.002_bib0024","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/bcj.2011.34","article-title":"Comorbidity as a prognostic variable in multiple myeloma: comparative evaluation of common comorbidity scores and use of a novel MM-comorbidity score","volume":"1","author":"Kleber","year":"2011","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.002_bib0025","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1016\/S1470-2045(12)70259-0","article-title":"Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review","volume":"13","author":"Hamaker","year":"2012","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1053\/j.seminoncol.2022.01.002_bib0026","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.002_bib0027","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.002_bib0028","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3324\/haematol.2019.242958","article-title":"Structured assessment of frailty in multiple myeloma as a paradigm of individualized treatment algorithms in cancer patients at advanced age","volume":"105","author":"Engelhardt","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2022.01.002_bib0029","series-title":"Physical Rehabilitation","first-page":"844","article-title":"Chapter 32 - Gait Assessment and Training","author":"AloopR","year":"2007"},{"issue":"8","key":"10.1053\/j.seminoncol.2022.01.002_bib0030","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jgo.2020.05.004","article-title":"Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment","volume":"11","author":"Mian","year":"2020","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.002_bib0031","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11136-015-1110-8","article-title":"Mode of administration does not cause bias in patient-reported outcome results: a meta-analysis","volume":"25","author":"Rutherford","year":"2016","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.002_bib0032","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.2196\/cancer.6996","article-title":"Electronic-based patient-reported outcomes: willingness, needs, and barriers in adjuvant and metastatic breast cancer patients","volume":"3","author":"Hartkopf","year":"2017","journal-title":"JMIR Cancer"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.002_bib0033","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s41687-020-00212-x","article-title":"Personalized symptom management: a quality improvement collaborative for implementation of patient reported outcomes (PROs) in 'real-world' oncology multisite practices","volume":"4","author":"Howell","year":"2020","journal-title":"J Patient Rep Outcomes"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.002_bib0034","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.002_bib0035","doi-asserted-by":"crossref","first-page":"e18982","DOI":"10.2196\/18982","article-title":"Adaptation and evaluation of a symptom-monitoring digital health intervention for patients with relapsed and refractory multiple myeloma: pilot mixed-methods implementation study","volume":"4","author":"Biran","year":"2020","journal-title":"JMIR Form Res"},{"issue":"7","key":"10.1053\/j.seminoncol.2022.01.002_bib0036","doi-asserted-by":"crossref","first-page":"E178","DOI":"10.1002\/ajh.25815","article-title":"Patient-reported outcome measures in multiple myeloma: Real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial","volume":"95","author":"Moore","year":"2020","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.002_bib0037","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0197-2456(00)00056-8","article-title":"The phase II\/III transition. Toward the proof of efficacy in cancer clinical trials","volume":"21","author":"Fazzari","year":"2000","journal-title":"Control Clin Trials"},{"key":"10.1053\/j.seminoncol.2022.01.002_bib0038","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cct.2017.11.002","article-title":"Wearable activity monitors in oncology trials: current use of an emerging technology","volume":"64","author":"Gresham","year":"2018","journal-title":"Contemp Clin Trials"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.002_bib0039","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.clbc.2019.05.005","article-title":"Fitbit usage in patients with breast cancer undergoing chemotherapy","volume":"19","author":"Dreher","year":"2019","journal-title":"Clin Breast Cancer"},{"issue":"Supplement 1","key":"10.1053\/j.seminoncol.2022.01.002_bib0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-142082","article-title":"Association of patient activity bioprofiles with hrqol and clinical responses: a prospective novel trial using mobile wearables in newly diagnosed multiple myeloma patients","volume":"136","author":"Neha Korde","year":"2020","journal-title":"Blood"},{"issue":"S1","key":"10.1053\/j.seminoncol.2022.01.002_bib0041","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.HS9.0000561200.43482.59","article-title":"proteasome inhibition (LTPI) in patients (PTS) with newly diagnosed multiple myeloma (NDMM): US MM-6, a real-world (RW) study transitioning from bortezomib (BTZ) to ixazomib (IXA)","volume":"3","author":"Rifkin","year":"2019","journal-title":"HemaSphere"},{"issue":"11","key":"10.1053\/j.seminoncol.2022.01.002_bib0042","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-009576","article-title":"Multiple myeloma and physical activity: a scoping review","volume":"5","author":"Smith","year":"2015","journal-title":"BMJ Open"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.002_bib0043","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/s41416-020-0866-y","article-title":"Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design","volume":"123","author":"Koutoukidis","year":"2020","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1053\/j.seminoncol.2022.01.002_bib0044","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jgo.2020.11.003","article-title":"Physical activity is associated with less co-morbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation","volume":"12","author":"M\u00f6ller","year":"2021","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.002_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-033176","article-title":"PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma","volume":"10","author":"McCourt","year":"2020","journal-title":"BMJ Open"},{"issue":"3","key":"10.1053\/j.seminoncol.2022.01.002_bib0046","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1046\/j.1365-2141.1996.352889.x","article-title":"Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group","volume":"92","author":"Wisl\u00f8ff","year":"1996","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.002_bib0047","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2022.01.002_bib0048","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-8-79","article-title":"Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma","volume":"8","author":"Kvam","year":"2010","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.002_bib0049","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.057","article-title":"Quality of life assessment in multiple myeloma patients undergoing dose-reduced tandem autologous stem cell transplantation","volume":"3","author":"Khalafallah","year":"2011","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.002_bib0050","first-page":"117","article-title":"Quality of life among patients with hematological cancer in a Malaysian hospital","volume":"66","author":"Priscilla","year":"2011","journal-title":"Med J Malaysia"},{"issue":"12","key":"10.1053\/j.seminoncol.2022.01.002_bib0051","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00277-011-1224-1","article-title":"Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial","volume":"90","author":"Verelst","year":"2011","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1053\/j.seminoncol.2022.01.002_bib0052","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2012.074534","article-title":"Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial","volume":"98","author":"Dimopoulos","year":"2013","journal-title":"Haematologica"},{"issue":"10","key":"10.1053\/j.seminoncol.2022.01.002_bib0053","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1053\/j.seminoncol.2022.01.002_bib0054","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3109\/10428194.2013.847933","article-title":"Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged \u2265 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial","volume":"55","author":"Dimopoulos","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.002_bib0055","first-page":"417","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.002_bib0056","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"key":"10.1053\/j.seminoncol.2022.01.002_bib0057","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"issue":"32","key":"10.1053\/j.seminoncol.2022.01.002_bib0058","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","article-title":"Health-related quality-of-life results from the open-label, randomized, phase III aspire trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma","volume":"34","author":"Stewart","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2022.01.002_bib0059","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/10428194.2017.1334125","article-title":"Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone","volume":"59","author":"Vogl","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1053\/j.seminoncol.2022.01.002_bib0060","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00277-018-3469-4","article-title":"Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study","volume":"97","author":"Cella","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminoncol.2022.01.002_bib0061","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25134","article-title":"Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma","author":"Leleu","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.002_bib0062","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.15459","article-title":"Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study","volume":"182","author":"Royle","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.seminoncol.2022.01.002_bib0063","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11136-019-02307-5","article-title":"Health-related quality of life of carfilzomib- and daratumumab-based therapies in patients with relapsed\/refractory multiple myeloma, based on German benefit assessment data","volume":"29","author":"Weisel","year":"2020","journal-title":"Qual Life Res"},{"issue":"6","key":"10.1053\/j.seminoncol.2022.01.002_bib0064","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3324\/haematol.2019.222299","article-title":"Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study","volume":"105","author":"Nielsen","year":"2020","journal-title":"Haematologica"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775422000021?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775422000021?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:57:12Z","timestamp":1758805032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775422000021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0093775422000021"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.002","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Examining health related quality of life outcomes in multiple myeloma: Past and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2022.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}